Amitriptyline reverses hyperalgesia and improves associated mood-like disorders in a model of experimental monoarthritis

dc.contributor.authorAmorim, Dianapor
dc.contributor.authorPereira, Ana Davidpor
dc.contributor.authorPertovaara, Anttipor
dc.contributor.authorAlmeida, Armandopor
dc.contributor.authorRibeiro, Filipa Pintopor
dc.date.accessioned2015-01-19T16:29:01Z
dc.date.available2015-01-19T16:29:01Z
dc.date.issued2014
dc.date.updated2015-01-16T15:46:21Z
dc.description.abstractAffective disorders are common comorbidities of chronic inflammatory pain that are often overlooked in primary care. As the impact of inflammatory pain upon mood-like disorders in animal models is not well known, our objective was to assess whether prolonged experimental monoarthritis (ARTH) induced the development of anxiety and depressive-like behaviours in rodents and if amitriptyline, an antidepressant commonly used in the treatment of chronic pain, could reverse both nociceptive and mood-like impairments. Experimental ARTH was induced through an injection of kaolin/carrageenan into the right knee joint with control (SHAM) animals injected with saline. Four weeks after induction, ARTH animals displayed mechanical hyperalgesia and a depressive-like phenotype as they showed a significant increase in immobility and a decrease in the latency to immobility in the forced-swimming test at the expense of the time spent climbing/swimming. ARTH animals also displayed a decreased sucrose preference, an index of anhedonia and anxiety-like behaviour as time spent exploring the open arms of the elevated-plus-maze was decreased when compared to controls. The anxiety-like phenotype was also supported by an increase in the number of fecal boli left in the open field. In ARTH animals, the administration of amitriptyline decreased mechanical hyperalgesia and increased sucrose preference and the time spent climbing, although it had a deleterious effect in the performance of control animals. Our data show that this model of ARTH can be useful for the study of chronic pain-mood disorders comorbidities and that amitriptyline is able to partly reverse the associated nociceptive and emotional impairments.por
dc.description.sponsorshipThis study was supported by grants from the Portuguese Science Foundation (FCT) Project no PTDC/SAU-NEU/108557/2008, FEDER-COMPETE, and the Academy of Finland. Diana Amorim was supported by FCT grant SFRH/BD/71219/2010. Ana David-Pereira was supported by FCT grant SFRH/BD/90374/2012.por
dc.distributioninternationalpor
dc.identifier.doi10.1016/j.bbr.2014.02.003por
dc.identifier.issn0166-4328por
dc.identifier.issn1872-7549por
dc.identifier.pmid24518202por
dc.identifier.urihttps://hdl.handle.net/1822/32982
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherElsevierpor
dc.relation.publisherversionhttp://www.sciencedirect.com/science/article/pii/S0166432814000709#por
dc.rightsopenAccesspor
dc.subjectExperimental monoarthritispor
dc.subjectPain-mood disorders comorbiditypor
dc.subjectMechanical hyperalgesiapor
dc.subjectAmitriptylinepor
dc.subject.wosScience & Technologypor
dc.titleAmitriptyline reverses hyperalgesia and improves associated mood-like disorders in a model of experimental monoarthritispor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationEndPage21por
oaire.citationStartPage12por
oaire.citationTitleBehavioural brain researchpor
oaire.citationVolume265por
sdum.journalBehavioural Brain Researchpor
sdum.publicationstatuspublishedpor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
amorim d_behav brain res 2014 prep.pdf
Tamanho:
699.5 KB
Formato:
Adobe Portable Document Format